Lung cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• EGFR 301
• PD-L1 162
• PD-1 157
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 90+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

  NCT05378763· Spectrum Pharmaceuticals, Inc· Updated 28 Oct 2026

  “The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.”Registry text, quoted unchanged. Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

  NCT05477615· Jin Hyoung Kang· Updated 8 Oct 2026

  “Slow accrual; enrollment was closed after 14 of 28 planned participants.”Registry text, quoted unchanged. Source

• Terminated

  A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

  NCT04844073· Takeda· Updated 24 Sept 2026

  “Sponsor decision based on limited anti-cancer activity of TAK-186.”Registry text, quoted unchanged. Source

• Terminated

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Updated 22 Sept 2026

  “Closed due to slow accrual.”Registry text, quoted unchanged. Source

• Terminated

  Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

  NCT03891615· Massachusetts General Hospital· Updated 21 Sept 2026

  “Slow accrual.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

  NCT06186076· Therapex Co., Ltd· Updated 2 Apr 2026

  “Sponsor's decision”Registry text, quoted unchanged. Source

• Terminated

  Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

  NCT05636267· Akeso· Updated 9 Mar 2026

  “Terminated due to sponsor strategic development reprioritization.”Registry text, quoted unchanged. Source

• Terminated

  Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

  NCT03066206· M.D. Anderson Cancer Center· Updated 20 Feb 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

  NCT05578092· Mirati Therapeutics Inc.· Updated 19 Feb 2026

  “business objectives have changed”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Bristol-Myers Squibb· Source

• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· AstraZeneca· Source

• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Janssen Research & Development, LLC· Source

• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  NCT04181060· National Cancer Institute (NCI)· Source

• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

  NCT04988295· Janssen Research & Development, LLC· Source

• Premedication to Reduce Amivantamab Associated Infusion Related Reactions

  NCT05663866· Janssen Research & Development, LLC· Source

• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Janssen Research & Development, LLC· Source

• A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

  NCT04077463· Janssen Research & Development, LLC· Source

• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Janssen Research & Development, LLC· Source

• A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT05388669· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 616
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 115
• Machine Learning 290
• Deep Learning 210
• Cohort Studies 289
• Genome-Wide Association Study 75

See which targets of this disease your abstract mentions, and go to the people working on them.